Limón-Jiménez E, Pineda Flores SA, Rodríguez-Wong U

Language: Spanish
References: 17
Page: 188-192
PDF size: 157.32 Kb.

ABSTRACT

Fibrinolytic drugs group acting at the level of conversion of inactive plasminogen to active, mediated plasminogen activator (t-PA). Streptokinase is an important drug that alters the coagulation process, and as it is imperative to know its clinical applications, should not put aside the pharmacological primary aspects of this substance, that such drug meets the requirements of pharmacodynamics and pharmacokinetics, leads us to use in medical practice, with remarkable skill and prudence.

REFERENCES

1. Lucas MA, Fretto LJ, Mckee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 1983.

2. Robbins KC, Summaria L, Hsieh B, Shah RJ. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 1967; 242: 2333-42.

3. Collen D, Bounameaux H, De Cook F, Lijnen HR, Verstraete M. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986; 73: 511-7.

4. Tillet WS, Garner RL. The fibrinolyticy activit of hemolytic streptococci. J Exp Med 1933; 58: 485-502.

5. Tillet WS, Sherry S. The effect in patients of streptococcal desoxyribonuclease on fibrinous, purulent and sanguinous pleural exudations. J Clin Invest 1949; 28: 173-90.

6. Tillet WS, Johnson AJ. The intavenous infusion of the streptoccocal fibrinolytic principle (streptokinase) into patients. J Clin Invest 1955; 34: 169-85.

7. Chibber BAK, Castellino FJ. Regulation of the streptokinasemediated activation of human plasminogen by fibrinogen and chloride ions. J Biol Chem 1986; 261: 5289-95.

8. Marder VJ, Sherry S. Thombolytic therapy current status. N Engl J Med 1988; 318: 1512-20, 1585-95.

9. Verstraete M. Biochemical and clinical aspects of thrombolysis. Semin Hematol 1978; 15: 35-54.

10. Gruppo italiano per lo Studio della Streptochinasi nell infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.

11. ISIS-2 (Second International Study of Infarct Survival) Colaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17.187 cases of suspected acute myocardial infarction; ISIS-2. Lancet 1988; ii: 349-60.

12. René A, Ron H. Adult Respiratory Distress Syndrome After Streptokinase. Am J Cardiol 1992; 70: 1632-3.

13. Fears R, Ferres H, Glasgow E, Standring R, Hogg K, et al. Monitoring of Streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase Ig G. Br Heart J 1992; 68: 167-70.

14. Jalihal S, Morris GK. Antistreptokinase titres after intravenous streptokinase. Lancet 1990; 335: 184-5.

15. Garg Shaila, Chandrashekhar YS, Nanda Kumar DM. Antistreptokinase Antibodies Before and After Streptokinase Therapy in Patients with Acute Myocardial Infarction from Areas Endemic for Streptococcal Infection and Influence on Reperfusion Rates. Am J Cardiol 1994; 74: 187-9.

16. MINSAP, Aplicación del tratamiento con estreptoquinasa Recombinante en el tratamiento del IMA. Potocolo Nacional. Centro de Ingeniería Genética y Biotecnología, Cuba, 1992.

17. Cigales MJ. Dolor lumbar por estreptoquinasa recombinante. Presentación de un caso. Rev Cubana Farm 2009; 43: 1-6.